Psoriasis is a chronic inflammatory disorder affecting the skin and joints that has a major impact on socioeconomic aspects of a patient’s life. In addition to the skin and joint disease, patients with psoriasis have a high risk of depression, anxiety, and may develop suicidal tendencies.

    More than 125 million individuals (2–3% of global population) are affected by psoriasis and 30% of them also develop Psoriatic Arthritis (PsA).

    INHIBITEC is developing a new approach to address these diseases through the development an novel monoclonal Antibody (mAb)

    Our monoclonal antibody (mAb) works against BAMBI (BMP and Activin Membrane-Bound Inhibitor). BAMBI is a transmembrane molecule that inhibits a key signal pathway that controls two lymphoid subpopulations with opposed roles in the pathogenesis of autoimmune diseases. The pharmacological inhibition of BAMBI. Altogether, our studies identify BAMBI as a new promising target in PsA and demonstrate the utility of B101.37 mAb in its treatment.

    In our pre clinical tests performed by the company and our partners at the University of Cantabria and CSIC, we have seen very succesful results with our Murine models against Psoriatic Arthritis. Our technology is protected by a patent wich ownership is by the Spanish National Research Council (CSIC) and the University of Cantabria (UC), that INHIBITEC has an exclusive commercialization and exploitation license.